The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Seminar Title
Seminar PH1 – “Wonder pills”, breakthroughs and continuing challenges – HIV and Hepatitis C antiviral treatments revisited
Affiliation
Medical University of Vienna
Country
Austria
1. Current Status, Position
Harald Hofer is a medical specialist for Gastroenterology and Hepatology at the Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Austria. Currently he is Head of Outpatient Clinic and Director of the Viral hepatitis programme.
2. Education
Prof. Dr. Hofer trained in Medicine at the University of Vienna. After a post doc, he finished his speciality board in Internal Medicine, Gastroenterology and Hepatology as well as Intensive Care Medicine. He has participated in more than 50 national and international clinical trials on viral hepatitis and has received numerous research grants. Prof. Dr. Hofer is a member of several national and international societies, and has been a governing board member of the Austrian Society of Gastroenterology and Hepatology since 2012. In 2003, he was awarded the Wewalka Prize of the Austrian Society of Gastroenterology and Hepatology. Prof. Dr. Hofer currently has about 80 publications in peer-reviewed journals, as well as several book chapters and reviews.
3. Research Area
Prof. Dr. Hofer’s current focus of research is viral hepatitis and autoimmune liver disease.
4. Conflict of interest: He has received speaker fees from Gilead, AbbiVie, Merck Sharp & Dohme and Bristol-Myers Squibb, is a consultant for Gilead and AbbVie and is in the advisory board of AbbVie and Bristol-Myers Squibb.